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Abstract
Background: Dysfunctionally uncoupled endothelial nitric oxide synthase (eNOS) is involved in
producing reactive oxygen species (ROS) in the diabetic endothelium. The present study
investigated whether anti-diabetes drug Aminoguanidine (AG) has any effect on eNOS function and
vascular oxidant stress.
Methods and Results: Blood glucose levels were increased to 452.0 ± 15.1 mg/dl in STZ-treated
male C57BL/6J mice (148.4 ± 3.2 mg/dl in untreated controls). Aortic productions of NO• and O2
￿-
were measured specifically and sensitively using electron spin resonance. Diabetic mice had a
marked increase in aortic O2
￿- production. Aortic hydrogen peroxide (H2O2) production was also
increased in diabetic aortas and significantly attenuated by AG. AG however had only a marginal
effect in reducing aortic O2
￿- production, which corresponded to a minimal effect in improving
aortic nitric oxide (NO￿) bioavailability. The endothelium-dependent vasodilatation however was
modestly but significantly improved by AG, likely consequent to AG-induced reduction in hyper-
contractility. NAD(P)H oxidase (NOX)-dependent O2
￿- production was completely attenuated by
AG in endothelium-denuded diabetic aortas.
Conclusion: In summary, despite that AG is not an effective eNOS recoupling agent presumably
consequent to its ineffectiveness in preventing endothelial NOX activation, it is inhibitory of aortic
H2O2 production, VSMC NOX activity, and hypercontractility in diabetes.
Background
Cardiovascular complications are the primary causes of
mortality in diabetic patients [1,2]. Accumulating evi-
dence has demonstrated that increased production of
reactive oxygen species (ROS) contributes to etiology of
diabetes [3-6] and its cardiovascular complications [4,6-
11]. Various enzymatic systems have been shown respon-
sible for diabetic oxidant stress, including xanthine oxi-
dase [12], NAD(P)H oxidase [13,14], and the more
recently established, uncoupled endothelial nitric oxide
synthase (eNOS) [15,16]. Oxidant stress contributes to
diabetic vascular damages by acceleration of advanced
glycation end products (AGEs) formation, modulation of
extracellular matrix proteins, promotion of cell prolifera-
tion and migration, stimulation of kinases and proinflam-
matory proteins, and importantly, inactivation of nitric
oxide (NO•), all of which are closely associated with the
pathogenesis of diabetic vascular complications [17,18].
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Aminoguanidine (AG) is one of the most extensively used
inhibitors of AGEs accumulation. Beneficial effects in pre-
venting cardiovascular events in diabetic rats have been
observed with AG treatment, likely attributed to its effects
on stopping AGE formation [19]. Besides its inhibitory
action on AGE formation, AG acts as a competitive and
selective inhibitor for inducible nitric oxide synthase
(iNOS) [20]. This action of AG has been known to be
associated with reduction of peroxinitrite (ONOO-),
which has deleterious roles in inducing NO￿ deficiency
and cellular damages through degradation of eNOS cofac-
tor, and inductions of inflammation, lipid peroxidation,
protein nitrosylation and DNA fragmentation [18,21,22].
Previous investigations have also demonstrated that AG
reduced hydrogen peroxide (H2O2) induced intracellular
hydroxyl radical formation and apoptosis, further demon-
strating a potential antioxidant activity [23,24]. These
multiple actions of AG may improve endothelial function
in diabetes independent of its AGE-inhibiting activity
[22,23]. Apart from its beneficial effects, high dose of AG
is associated with some adverse effects such as autoim-
mune symptoms, abnormal liver function, gastrointesti-
nal disturbance, and flu-like symptoms [25,26]. These
side effects are likely related to its structural similarities to
hydrazine, an inducing factor of lupus like syndrome, and
L-arginine, a substrate of NO￿ synthase [27]. Thus the
potential effect of AG is complex in diabetes associated
cardiovascular complication. The direct impact of AG on
aortic oxidant stress and eNOS function is completely
unknown despite that AG was found to suppress superox-
ide (O2
￿-) production, mitochondrial complex III activity
and eNOS uncoupling in the kidney [26,28].
Therefore, in the present study we treated STZ-induced dia-
betic mice in vivo with AG, and measured aortic O2
￿- and NO￿
productions by electron spin resonance (ESR) sensitively and
specifically. AG only marginally reduced total aortic O2
￿- pro-
duction although it significantly attenuated aortic hydrogen
peroxide (H2O2) generation. Endothelium-dependent
vasodilatation was modestly yet significantly improved
which was accompanied by AG-dependent significant reduc-
tion in aortic hypercontractility. NAD(P)H oxidase (NOX)-
dependent O2
￿- production in endothelium-denuded aortas
was significantly attenuated by AG, likely contributing to the
reduction in phenylephrine (PE)-induced hypercontractility.
These data seem to implicate that although AG is ineffective
in recoupling eNOS in diabetic aortas, it reduces vascular
H2O2 production and hypercontractility in diabetes, which
may in part account for its beneficial effects in preventing
vascular disease development.
Methods
Diabetic mice and drug interventions
Male C57BL/6J mice (6-8 weeks old) were obtained from
Jackson Laboratories. Mice were housed in a pathogen-
free condition. The Institutional Animal Care and Usage
Committee at the University of Chicago and University of
California Los Angeles approved the use of animals and
experimental procedures. Diabetes was induced by tail
vein injection of Streptozocin (STZ, 100 mg/Kg) dissolved
in 50 μL of 0.9% saline immediately before use, once a
day for three days [15,29,30]. Blood glucose was deter-
mined using the One Touch Ultra® blood glucose meter
(Lifescan) at baseline and on day four post STZ injection
for each individual mouse. On day four, STZ diabetic mice
were injected with Aminoguanidine (AG) [31] dissolved
in 0.9% saline via tail vein at 100 mg/kg/day for three
days. By day seven, animals were sacrificed using CO2
inhalation and whole aorta was removed, cleared from
surrounding connective tissues and cut transversely into 2
mm or 3 mm rings for subsequent experiments. Nitric
oxide production and vasoreactivity measurement was
performed with 2 mm of aorta segments and determina-
tion of superoxide and hydrogen peroxide level was con-
ducted with each 3 mm of aorta. This model of diabetes is
characterized by acute hyperglycemia. No renal dysfunc-
tion occurs during the study period of seven days [32].
Electron spin resonance measurement of aortic superoxide 
production
Freshly isolated aortas were placed into chilled modified
Krebs/HEPES buffer (composition in mmol/L: 99.01
NaCl, 4.69 KCl, 2.50 CaCl2, 1.20 MgSO4, 1.03 KH2PO4,
25.0 NaHCO3, 20.0 Na-HEPES, and 5.6 glucose [pH
7.4]), cleaned of excessive adventitial tissue, with care
taken not to injure the endothelium. The specific O2
￿- spin
trap methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine
(CMH, 500 μmol/L, Alexis) solution was prepared freshly
in nitrogen gas bubbled Krebs/HEPEs buffer containing
diethyldithiocarbamic acid (DETC, 5 μmol/L Sigma) and
deferoxamine (25 μmol/L, Sigma). Aortic segment (~3
mm) was then mixed with the spin trap solution and
loaded into glass capillary (Fisher Scientific) for analysis
of O2
￿- signal (CM￿ formed after trapping O2
￿-) using the
electron spin resonance (ESR) spectrometer (Miniscope
MS200, Magnettech, Germany). Some of the intact or
endothelium-denuded aortic segments were incubated in
presence or absence of NSC23766 (200 nmol/L, 90 min)
to detect NOX sensitive superoxide production. The ESR
settings used were bio-field, 3350; field sweep, 45.00 G (1
G = 0.1 mT); microwave frequency, 9.78 GHz; microwave
power 7 dB (20 mW); modulation amplitude, 3000 mG;
4,096 points of resolution; and receiver gain, 700.
Amplex-Red assay for hydrogen peroxide production
Freshly isolated aortic rings (4 × 2 mm) were used for
assessment of H2O2  production using a fluorometric
horseradish peroxidase assay (Amplex-Red assay, Molecu-
lar Probes). Fluorescence was measured (excitation 530
nm and emission 590 nm) after 1 hour incubation at
37°C in dark against background fluorescence of buffer.
Polyethylene glycol conjugated catalase (PEG-CAT, 300Cardiovascular Diabetology 2009, 8:65 http://www.cardiab.com/content/8/1/65
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U/ml, Sigma)-inhibitable fraction reflects specific H2O2
signal. The rate of H2O2 production was presented as
pmol/mg protein/min after calculation according to a
standard curve generated using fresh H2O2 in reaction
buffer [33].
Electron spin resonance of aortic nitric oxide production
Freshly isolated aortic rings (6 × 2 mm) were incubated
with freshly prepared NO￿-specific spin trap Fe2+(DETC)2
(0.5 mmol/L) in modified Kreb's HEPES buffer (KHB) at
37°C for 60 min [spin trap and buffer recipe see above
and previous publication [34], in the presence or absence
of calcium ionophore A23187 (10 μmol/L). After the
incubation, the aorta in KHB was snap-frozen in liquid
nitrogen and loaded into a finger Dewar for analysis with
ESR spectrophotometer. The instrument settings were as
the followings: bio-field, 3280; field sweep, 77.54 G (1 G
= 0.1 mT); microwave frequency, 9.78 GHz; microwave
power, 4 dB (40 mW); modulation amplitude, 10 G;
4,096 points of resolution; and receiver gain, 900.
Assessment of vascular reactivity
Freshly prepared aortic rings (2 mm) were placed in organ
baths containing modified Kreb's HEPES buffer(recipe see
above), aerated with a mixture of 95% oxygen/5% carbon
dioxide and maintained at 37°C. After being kept under 5
mN tension for 90 min to stabilize, cumulative tension
was measured by a Graz Tissue Bath System (Hugo Sachs
Elektronik/Harvard Apparatus GmbH, March Hugstetten,
Germany) connected to a The MP100 workstations (Bio-
Pac Systems). Relaxation curve to acetylcholine (10-9 to
10-6 M) were assessed in aortic segment after contraction
by phenylephrine (PE, 5 μmol/L). Data acquisition proc-
ess and post-acquisition calculations were performed with
AcqKnowledge software (BioPac Systems).
Statistical analysis
Differences among different groups of means were com-
pared with unpaired t-test for two means and ANOVA for
multiple means. Statistical significance was set for p <
0.05. All grouped data shown in the figures were pre-
sented as mean ± SEM.
Results
Effect of Aminoguanidine on hyperglycemia
Diabetic mice were created by streptozotocin (STZ)
administration. On day of harvest (7-8th day after initial
STZ injection, same hereafter), blood glucose was elevated
to 452.0 ± 15.1 mg/dl in diabetic mice vs 148.4 ± 3.2 mg/
dl in the C57BL6 controls. AG (100 mg/kg/day, same
hereafter) treatment since day 4 had no significant effect
on STZ induction of hyperglycemia (data not shown).
Effect of Aminoguanidine on aortic superoxide production
Aortic production of O2
￿-, etected specifically by electron
spin resonance (ESR) and a cell-permeable specific spin
trap, was more than doubled in diabetic mice (control vs
diabetics: 3.3 ± 1.6 vs 7.0 ± 2.6 nmol/L per min per mg
wet weight of aorta, p < 0.05). AG attenuated this
response however marginally and insignificantly, as dem-
onstrated by both representative ESR spectra and grouped
data (Figs. 1A&B).
Effect of Aminoguanidine on aortic hydrogen peroxide 
production
Aortic H2O2 was detected specifically using an Amplex
Red Assay (details see Methods section). Diabetic mice
had a more than 4-fold increase in H2O2 production (5.86
± 1.21 vs 22.39 ± 3.61 pmol/mg protein/min for control
vs diabetics), which was significantly attenuated by treat-
ment with AG (9.77 ± 4.71 pmol/mg protein/min, Fig.
2A, p < 0.05).
Effects of AG on aortic superoxide (O2
￿-) production Figure 1
Effects of AG on aortic superoxide (O2
•-) production. 
A: Representative spectra for aortic O2
￿- detected by ESR. 
Freshly isolated aortic segments (~3 mm) were incubated 
with spin trapping solution and then analyzed using ESR. B: 
Grouped data of aortic O2
￿- production expressed as nmol/L 
per min per mg wet weight. Data are presented as mean ± 
SEM, n = 6-8.
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Aminoguanidine failed to restore aortic NO• production
Aortic NO￿ production was directly and characteristically
detected using ESR. As shown in representative ESR spec-
tra and grouped data (Figs. 3A&B), diabetic mice had
markedly reduced bioavailable NO￿ (0.50 ± 0.08 in diabe-
tes vs 0.72 ± 0.10 nmol/mg dry weight) and this response
was however not significantly affected by treatment with
AG (0.55 ± 0.15 nmol/mg dry weight). This result indi-
cated that AG was ineffective in fully restoring eNOS func-
tion.
Aminoguanidine partially restored endothelium-
dependent vasorelaxation: Role of attenuation of 
hypercontractility?
Interestingly, although AG did not protect NO￿ bioavaila-
bility likely due to its insignificance in reducing O2
￿- pro-
duction from eNOS, AG partially yet significantly restored
endothelium-dependent vasorelaxation (Fig. 4A). Intrigu-
ingly, diabetic aortas exerted a more than 3-fold increase
in basal contractility in response to PE, which was mark-
edly attenuated by AG (Fig. 4B). Vascular smooth muscle
cell (VSMC) production of O2
￿- has been implicated in the
hypercontractile response in diabetic blood vessels
[35,36]. Furthermore, the source of this O2
￿- production
could be NAD(P)H oxidase (NOX) [35]. Previously we
have successfully measured O2
￿-  production from
endothelium-denuded vessels in the presence of NOX
inhibitor. As shown in Fig. 5, consistent to previous find-
ings, NOX remained active in VSMC [16]. AG completely
diminished NSC23766-sensitive O2
￿- production, indicat-
ing that attenuation of NOX may have accounted for
reduced hypercontracility observed with AG, which was
further linked to improved vasorelaxation.
It is important to emphasize that in the intact endothe-
lium, uncoupled eNOS is the primary source of ROS pro-
duction 7 days after STZ injection [16]. This is presumably
consequent to a transient activation of endothelial NOX
based on our in vitro data from cultured aortic endothelial
cells [34]. In this earlier study we found that, via transient
activation endothelial NOX, angiotensin II (Ang II)
induces H2O2 dependent eNOS uncoupling. Indeed, we
found that in vivo treatment with Ang II signaling attenu-
ators candesartan or captopril completely prevented
eNOS uncoupling in diabetes [16].
We also found that after removal of endothelium to allow
sufficient spin trap penetration to the underneath VSMC,
NOX-dependent O2
￿- production remained elevated by day
7, which was found attenuated by candesartan or captopril
previously, and now by AG. Therefore we believe that
although AG may not have any effects on the endothelial
NOX isoform in contrast to the Ang II attenuators, it is effec-
tive in inhibiting the VSMC NOX isoform. We are working
on follow-up studies to identify cell-specific NOX isoforms
that are involved in the eNOS uncoupling and NOX activa-
tion in diabetic endothelial cells and VSMC. These would be
however beyond the scope of the present study.
Discussion
The present study systematically studied effects of AG on
vascular oxidant stress, eNOS function and endothelium-
Effects of AG on aortic hydrogen peroxide (H2O2) produc- tion Figure 2
Effects of AG on aortic hydrogen peroxide (H2O2) 
production. Total aortic H2O2 production by Amplex Red 
Assay. Data are presented as mean ± SEM, n = 8.
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dependent vasorelaxation. Whereas AG only partially
reduced vascular O2
￿- production, it attenuated H2O2 pro-
duction significantly and improved endothelium-depend-
ent vasodilatation, likely via a reduction in NOX-linked
hypercontractility. Although AG does not seem to be an
effective eNOS recoupling agent like Ang II signaling
attenuators [16], it may still exert beneficial effects via
attenuating VSMC NOX activity and H2O2 production.
Oxidant stress has been implicated in micro and macrov-
ascular complication of diabetes [37]. Moreover, excessive
generation of O2
￿- in endothelium by hyperglycemia has
been considered one of the major factors involved in
accelerating vascular complications. Recent studies have
shown that eNOS uncoupling is the primary source of
O2
￿-  production in the diabetic endothelium [15,16],
whereas NAD(P)H oxidase remain active in sub-endothe-
lial VSMC [16]. eNOS uncoupling is a phenomenon
whereby the enzyme generates O2
￿- rather than NO￿. Pre-
viously we established that increased O2
￿- production in
STZ-induced diabetic mice is attributed to eNOS uncou-
pling, which was significantly attenuated by Ang II signal-
ing blockers [16]. In the present study we examined effects
of AGE chain breaker AG in recoupling eNOS and found
AG failed to significantly reduce aortic O2
￿- production in
diabetes. AG also failed to significantly restore aortic NO￿
bioavailability. AG has been used as a iNOS inhibitor
because of its structure similarity with L-arginine; and it is
also known as a weaker inhibitor for eNOS [27,38].
Whether or not these are linked to the ineffectiveness of
AG in restoring NO￿ production however, remain unclear.
Despite lack of significant impacts on O2
￿-/NO￿ pathway,
AG significantly attenuated aortic H2O2 production in dia-
betic mice. It also significantly, though modestly,
improved endothelium-dependent vasodilatation, which
is likely consequent to a reduction in hypercontractility
that is associated with attenuation of VSMC NOX activity.
Ineffective eNOS recoupling agent that is, AG proved to be
Effects of AG on vascular reactivity Figure 4
Effects of AG on vascular reactivity. A: AG partially restored endothelium-dependent vasorelaxation. B: AG diminished 
diabetes induced aortic hypercontractility. Data are presented as mean ± SEM, n = 6.
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highly effective in attenuating diabetes-induced aortic
hypercontractility.
There have been controversial observations of diabetic
hypercontracility given species, age, diabetic type, diabetic
stage, and vessel types [14,39-43]. For instance, a recent
study by Su et al., showed that acetylcholine dependent
dilation was decreased in diabetes whereas there was no
difference between control and diabetic group in response
to PE, concluding no specific role of VSMC contraction in
type 2 diabetes [14]. Not in agreement with our data, they
observed that AG did not alter vasocontraction to PE, indi-
cating that AGE formation is not associated with muscle
contraction in type 2 diabetic mesenteric arteries [14]. On
the other hand, other studies demonstrated hypercontrac-
tility to PE in aortas of STZ-induced diabetes [44,45]. In
agreement with our results, AG normalized the response
to PE in STZ diabetic mice without affecting plasma glu-
cose levels [44]. Taken together, our results are consistent
with previous observations regarding effect of AG on vas-
cular hypercontraction in conduit vessels of early stage
type 1 diabetes, hence indicating a potential beneficial
effect of AG for prevention of cardiovascular complication
for this particular diabetic type and stage.
It has been hypothesized that the basal hypercontractility
is dependent on O2
￿- in STZ induced diabetic mice [36]. In
the denuded aortas of human diabetes, O2
￿- production
was also found elevated [35]. Indeed we have observed
that in the endothelium-denuded aortas, AG completely
attenuated NOX dependent O2
￿- production from VSMC
(Fig. 5). Theoretically this reduction in O2
￿- could feed
back to the endothelium to partially contribute to preser-
vation of NO￿ bioavailability. On the other hand, loss of
O2
￿- in VSMC may directly modulate VSMC contractility
via undefined mechanisms. It is interesting to speculate
that loss of NOX-derived O2
￿- in diabetic VSMC might
underlie AG reduction of hypercontractility.
Conclusion
In summary, AG has been examined systematically for its
effects on vascular oxidant stress, eNOS function and
endothelium-dependent vasorelaxation. To our knowl-
edge these are first endeavors. This agent was ineffective in
reducing plasma glucose levels, partially effective in inhib-
iting total O2
￿-, and insignificantly effective in improving
NO￿ bioavailability in diabetes. However, it reduced aor-
tic H2O2 production and improved endothelium-depend-
ent vasorelaxation while diminished hypercontractility of
aortas. Whether this is attributed to AG-dependent signif-
icant reduction in VSMC NOX activity remains to be fur-
ther elucidated.
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